PL1806130T3 - Kompozycja farmaceutyczna w postaci stałej zawierająca irbesartan - Google Patents

Kompozycja farmaceutyczna w postaci stałej zawierająca irbesartan

Info

Publication number
PL1806130T3
PL1806130T3 PL06000329T PL06000329T PL1806130T3 PL 1806130 T3 PL1806130 T3 PL 1806130T3 PL 06000329 T PL06000329 T PL 06000329T PL 06000329 T PL06000329 T PL 06000329T PL 1806130 T3 PL1806130 T3 PL 1806130T3
Authority
PL
Poland
Prior art keywords
irbesartan
solid pharmaceutical
pharmaceutical composition
active ingredient
present
Prior art date
Application number
PL06000329T
Other languages
English (en)
Inventor
Miha Vrbinc
Renata Jakse
Franci Bevec
Silvo Zupancic
Original Assignee
Krka D D Novo Mesto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Krka D D Novo Mesto filed Critical Krka D D Novo Mesto
Publication of PL1806130T3 publication Critical patent/PL1806130T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL06000329T 2006-01-09 2006-01-09 Kompozycja farmaceutyczna w postaci stałej zawierająca irbesartan PL1806130T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06000329A EP1806130B1 (en) 2006-01-09 2006-01-09 Solid pharmaceutical composition comprising irbesartan

Publications (1)

Publication Number Publication Date
PL1806130T3 true PL1806130T3 (pl) 2010-08-31

Family

ID=35744710

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06000329T PL1806130T3 (pl) 2006-01-09 2006-01-09 Kompozycja farmaceutyczna w postaci stałej zawierająca irbesartan

Country Status (15)

Country Link
US (1) US20110045097A1 (pl)
EP (2) EP1806130B1 (pl)
CN (1) CN101370484B (pl)
AT (1) ATE462414T1 (pl)
CA (1) CA2636663A1 (pl)
DE (1) DE602006013261D1 (pl)
EA (1) EA016579B1 (pl)
ES (1) ES2340701T3 (pl)
HR (1) HRP20100216T1 (pl)
NO (1) NO20083183L (pl)
PL (1) PL1806130T3 (pl)
PT (1) PT1806130E (pl)
SI (1) SI1806130T1 (pl)
UA (1) UA95274C2 (pl)
WO (1) WO2007080074A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006006588A1 (de) 2006-02-13 2007-08-16 Ratiopharm Gmbh Schnell freisetzende Irbesartan-haltige pharmazeutische Zusammensetzung
RU2465900C2 (ru) * 2007-04-17 2012-11-10 Рациофарм Гмбх Фармацевтические композиции, содержащие ирбесартан
EP2065035B1 (en) 2007-11-28 2010-07-21 Laboratorios Lesvi, S.L. Pharmaceutical formulations containing irbesartan
WO2011141783A2 (en) 2010-04-13 2011-11-17 Micro Labs Limited Pharmaceutical composition comprising irbesartan
CN101912390A (zh) * 2010-08-08 2010-12-15 浙江华海药业股份有限公司 含厄贝沙坦的药用组合物
CN103191076B (zh) * 2013-04-27 2016-08-17 吕丕平 一种厄贝沙坦片剂的制备方法
JP6445923B2 (ja) * 2015-04-22 2018-12-26 ダイト株式会社 イルベサルタン含有錠剤の調製方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270317A (en) * 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
IE910913A1 (en) 1990-03-20 1991-09-25 Sanofi Sa N-substituted heterocyclic derivates, their preparation¹and pharmaceutical compositions containing them
US5541209A (en) * 1994-08-22 1996-07-30 Bristol-Myers Squibb Company Method of treating or preventing cardiac arrhythmia employing an N-substituted heterocyclic derivative
FR2725987B1 (fr) 1994-10-19 1997-01-10 Sanofi Sa Procede pour la preparation d'un derive de tetrazole sous deux formes cristallines et nouvelle forme cristalline de ce derive
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
FR2780403B3 (fr) 1998-06-24 2000-07-21 Sanofi Sa Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
TWI324074B (en) * 2001-10-09 2010-05-01 Bristol Myers Squibb Co Flashmelt oral dosage formulation
CA2469656A1 (en) 2001-12-10 2003-06-19 Dr. Reddy's Laboratories Limited Amorphous form of 2-n-butyl-3-( (2-(1h-tetrazol-5-yl) (1,1'-biphenyl)-4-yl) methyl) -1,3-diazaspiro (4,4') non-1-en-4-one
ATE340793T1 (de) 2002-07-16 2006-10-15 Teva Pharma Neue synthese von irbesartan
TR200301553A1 (tr) * 2003-09-18 2005-10-21 Nobel �La� Sanay�� Ve T�Caret A.�. İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
DE602005025755D1 (de) * 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
WO2006013545A1 (en) * 2004-07-28 2006-02-09 Ranbaxy Laboratories Limited Pharmaceutical compositions of irbesartan
SI21849A (sl) * 2004-07-29 2006-02-28 Krka, Tovarna Zdravil, D.D., Novo Mesto Priprava hidrokloridnih soli tetrazolskega derivata
GB2419592A (en) * 2004-10-26 2006-05-03 Cipla Ltd Process for the preparation of irbesartan hydrochloride
US20060160871A1 (en) * 2004-12-07 2006-07-20 Nektar Therapeutics Stable non-crystalline formulation comprising losartan
WO2006067601A1 (en) * 2004-12-23 2006-06-29 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of irbesartan and hydrochlorothiazide and processes for their preparation

Also Published As

Publication number Publication date
SI1806130T1 (sl) 2010-06-30
DE602006013261D1 (de) 2010-05-12
EP1981485B1 (en) 2014-10-08
EA016579B1 (ru) 2012-06-29
WO2007080074A1 (en) 2007-07-19
US20110045097A1 (en) 2011-02-24
CN101370484B (zh) 2011-06-01
HRP20100216T1 (hr) 2010-05-31
NO20083183L (no) 2008-09-26
EP1806130A1 (en) 2007-07-11
EA200801634A1 (ru) 2008-10-30
ATE462414T1 (de) 2010-04-15
PT1806130E (pt) 2010-05-11
UA95274C2 (ru) 2011-07-25
CN101370484A (zh) 2009-02-18
ES2340701T3 (es) 2010-06-08
CA2636663A1 (en) 2007-07-19
EP1981485A1 (en) 2008-10-22
EP1806130B1 (en) 2010-03-31

Similar Documents

Publication Publication Date Title
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
WO2006082523A3 (en) Pharmaceutical sustained release composition of metformin
WO2007017135A3 (en) Process for the preparation of olmesartan medoxomil
NO20083183L (no) Fast farmasoytisk sammensetning inneholdende irbesartan
WO2010136474A3 (en) Substituted aminobutyric derivatives as neprilysin inhibitors
WO2006002077A3 (en) Stable pharmaceutical formulations of benzimidazole compounds
UA96575C2 (en) Process for the preparation of olmesartan medoxomil
IL193252A0 (en) N-hydroxyacrylamide compounds
DK1820506T3 (da) Dipyridamol-formuleringer med forlænget frigivelse og fremgangsmåde til fremstilling heraf
UA96622C2 (ru) Твердые лекарственные формы, которые содержат алискирен, изготовленные способом сухого гранулирования
CY1112702T1 (el) Βελτιωμενη φαρμακευτικη συνθεση που περιεχει εναν αντισπασμωδικο παραγοντα πυρρολιδονης και μεθοδος για την παρασκευη της
MY144613A (en) Formulations of suberoylanilide hydroxamic acid and methods for producing same
ATE479427T1 (de) Pharmazeutische zusammensetzung mit candesartan- cilexetil
TW200744583A (en) Statin stabilizing dosage formulations
WO2008004100A9 (en) Therapeutic compounds
EP2077111A4 (en) ANTIDEPRESSANT AGENT
TW200640933A (en) Anthelmintic compounds
CY1114306T1 (el) Νεα συνθεση για τη θεραπευτικη αντιμετωπιση της ιδιοπαθους θρομβοκυτταραιμιας
WO2008039894A3 (en) Atorvastatin pharmaceutical compositions
WO2007110765A3 (en) Processes for the preparation of octreotide
WO2007083096A3 (en) N- (2, 3-difluorophenyl) -2- [4- ( {7-methoxy-5- [ (2r) -piperidin. -2-ylmethoxy] quinazoli n-4-yl}amino) -lh-pyrazol-1-yl] acetamide and n- (2, 3 -d i fluoro phenyl) -2- [4- ( {7-ethoxy-5- [ (2r) -piperidin. -2-ylmethoxy] quinazolin
TW200716114A (en) Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof
WO2007035816A3 (en) Paroxetine compositions
WO2007052167A3 (en) Stable composition for a pharmaceutical formulation containing olanzapine
TW200716115A (en) Immediate-release and high-drug-load pharmaceutical formulations of non-micronised (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof